Clinical trial · Observational
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
NCT02896829CI-TRIAL-00045619STIM-FUcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It's an observational study based on 98 patients included in the STIM trial to extend the monitoring of patients and to have molecular and clinical data, with long follow up. Are there late relapses? What has become patients who relapsed during STIM trial and restarted TKI (inhibitor tyrosine kinase) treatment?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interruption of the treatment by Imatinib | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Imatinib treatment ending
- description
- Interruption of the treatment by Imatinib
- interventionNames
- Behavioral: Interruption of the treatment by Imatinib
Primary outcomes (1)
- measure
- Assessment of the molecular status (BCR-ABL1 quantification by RT-qPCR) in the STIM1 population who stopped or restart a treatment by tyrosine kinase inhibitor (TKI)
- timeFrame
- up to five years
Secondary outcomes (3)
- measure
- Evaluation of rate of molecular relapse after imatinib discontinuation
- timeFrame
- up to five years
- measure
- Evaluation of duration of deep molecular response after stopping imatinib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patients should have been included in the STIM1 Study CHUBX 2006/06 (NCT00478985) Exclusion Criteria: * The patients not included or discharged prematurely from the STIM1 Study can not participate to the study
References
Publications (0)
Data not yet available
No reference posted for this study.